More from Xconomy.com:
Exelixis is a Motley Fool Rule Breakers recommendation.
Luke Timmerman is the National Biotechnology Editor for Xconomy, and the Editor of Xconomy Seattle. You can e-mail him at firstname.lastname@example.org, or call 206-624-2374.
More from The Motley Fool
4 Reasons Exelixis, Inc. More Than Doubled in 2017
A 104% gain last year wouldn't have been possible without lead drug Cabometyx.
3 Top Healthcare Stocks to Buy in January
These prominent drug developers look to be enticing buys this month.
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Hint: It has everything to do with lead drug Cabometyx.